David Solit

Cited by

	All	Since 2018
Citations	80165	51355
h-index	133	99
i10-index	352	315

11000

5500

2750

8250

20042005200620072008200920102011201220132014201520162017201820192020202120222023263 423 607 792 929 1176 1312 1595 2145 3067 3548 3840 3939 4257 5419 6943 8761 10328 10568 9119

Public access

View all

273 articles

11 articles

available

not available

Based on funding mandates

Co-authors

Neal RosenProfessor of Pharmacology, Memorial Sloan-Kettering Cancer CenterVerified email at mskcc.org
Hikmat Al-AhmadieMemorial Sloan Kettering Cancer CenterVerified email at mskcc.org
Michael F BergerMember, Memorial Sloan-Kettering Cancer CenterVerified email at mskcc.org
David M HymanLoxo Oncology, Eli LillyVerified email at loxooncology.com
Jonathan RosenbergAttending Physician, Memorial Sloan Kettering Cancer CenterVerified email at mskcc.org
Ahmet ZehirExecutive Director, Precision Medicine Innovation, AstraZenecaVerified email at astrazeneca.com
Eugene PietzakMemorial Sloan Kettering Cancer Center, Urology Service (Surgery)Verified email at mskcc.org
Gopa IyerMemorial Sloan Kettering Cancer CenterVerified email at mskcc.org
Irina OstrovnayaAssociate Attending Biostatistician, MSKCCVerified email at mskcc.org
Efsevia Vakiani MD PhDAssistant Attending, Memorial Sloan Kettering Cancer Center, New York, USAVerified email at mskcc.org
Christine PratilasJohns Hopkins UniversityVerified email at jhmi.edu
Nikolaus SchultzCenter for Molecular Oncology, Memorial Sloan Kettering Cancer CenterVerified email at cbio.mskcc.org
Victor E. ReuterMemorial Sloan Kettering Cancer CenterVerified email at mskcc.org
Manickam JanakiramanResearch Associate, Human Oncology and Pathogenesis Program (HOPP), Memorial Sloan-Kettering Cancer Center (MSKCC)Verified email at mskcc.org
Agnes VialeMemorial Sloan Kettering Cancer CenterVerified email at mskcc.org
Barry S. TaylorLoxo Oncology, Eli LillyVerified email at loxooncology.com
Jaclyn HechtmanMemorial Sloan Kettering Cancer CenterVerified email at mskcc.org
Paul ChapmanVerified email at mskcc.org
Qing-Bai SheProfessor of Molecular Pharmacology, University of KentuckyVerified email at uky.edu
Rona YaegerMemorial Sloan Kettering Cancer CenterVerified email at mskcc.org

David Solit

Director, Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center

Verified email at mskcc.org - Homepage

Cancer Biology and Genetics


Title Sort by citations Sort by year Sort by title	Cited by Cited by	Year
Comprehensive molecular characterization of human colon and rectal cancer Cancer Genome Atlas Network Nature 487 (7407), 330, 2012	7118	2012
mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt KE O'Reilly, F Rojo, QB She, D Solit, GB Mills, D Smith, H Lane, ... Cancer research 66 (3), 1500-1508, 2006	2927	2006
Tumor mutational load predicts survival after immunotherapy across multiple cancer types RM Samstein, CH Lee, AN Shoushtari, MD Hellmann, R Shen, ... Nature genetics 51 (2), 202-206, 2019	2822	2019
Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients A Zehir, R Benayed, RH Shah, A Syed, S Middha, HR Kim, P Srinivasan, ... Nature medicine 23 (6), 703-713, 2017	2735	2017
Comprehensive molecular characterization of urothelial bladder carcinoma Cancer Genome Atlas Research Network Nature 507 (7492), 315, 2014	2499	2014
Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer S Misale, R Yaeger, S Hobor, E Scala, M Janakiraman, D Liska, E Valtorta, ... Nature 486 (7404), 532-536, 2012	1953	2012
Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion R Straussman, T Morikawa, K Shee, M Barzily-Rokni, ZR Qian, J Du, ... Nature 487 (7408), 500-504, 2012	1905	2012
OncoKB: a precision oncology knowledge base D Chakravarty, J Gao, S Phillips, R Kundra, H Zhang, J Wang, ... JCO precision oncology 1, 1-16, 2017	1760	2017
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF (V600E) PI Poulikakos, Y Persaud, M Janakiraman, X Kong, C Ng, G Moriceau, ... Nature 480 (7377), 387-390, 2011	1588	2011
BRAF mutation predicts sensitivity to MEK inhibition DB Solit, LA Garraway, CA Pratilas, A Sawai, G Getz, A Basso, Q Ye, ... Nature 439 (7074), 358-362, 2006	1510	2006
Inherited DNA-repair gene mutations in men with metastatic prostate cancer CC Pritchard, J Mateo, MF Walsh, N De Sarkar, W Abida, H Beltran, ... New England Journal of Medicine 375 (5), 443-453, 2016	1479	2016
Molecular determinants of response to anti–programmed cell death (PD)-1 and anti–programmed death-ligand 1 (PD-L1) blockade in patients with non–small-cell lung cancer profiled … H Rizvi, F Sanchez-Vega, K La, W Chatila, P Jonsson, D Halpenny, ... Journal of clinical oncology 36 (7), 633, 2018	1152	2018
AACR Project GENIE: powering precision medicine through an international consortium AACR Project Genie Consortium, AACR Project GENIE Consortium, ... Cancer discovery 7 (8), 818-831, 2017	1111	2017
Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy D Chowell, LGT Morris, CM Grigg, JK Weber, RM Samstein, V Makarov, ... Science 359 (6375), 582-587, 2018	929	2018
Akt forms an intracellular complex with heat shock protein 90 (Hsp90) and Cdc37 and is destabilized by inhibitors of Hsp90 function AD Basso, DB Solit, G Chiosis, B Giri, P Tsichlis, N Rosen Journal of Biological Chemistry 277 (42), 39858-39866, 2002	762	2002
The genomic landscape of endocrine-resistant advanced breast cancers P Razavi, MT Chang, G Xu, C Bandlamudi, DS Ross, N Vasan, Y Cai, ... Cancer cell 34 (3), 427-438. e6, 2018	726	2018
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity MT Chang, S Asthana, SP Gao, BH Lee, JS Chapman, C Kandoth, JJ Gao, ... Nature biotechnology 34 (2), 155-163, 2016	708	2016
Genome sequencing identifies a basis for everolimus sensitivity G Iyer, AJ Hanrahan, MI Milowsky, H Al-Ahmadie, SN Scott, ... Science 338 (6104), 221-221, 2012	708	2012
Tumor adaptation and resistance to RAF inhibitors P Lito, N Rosen, DB Solit Nature medicine 19 (11), 1401-1409, 2013	639	2013
V600EBRAF is associated with disabled feedback inhibition of RAF–MEK signaling and elevated transcriptional output of the pathway CA Pratilas, BS Taylor, Q Ye, A Viale, C Sander, DB Solit, N Rosen Proceedings of the National Academy of Sciences 106 (11), 4519-4524, 2009	635	2009

The system can't perform the operation now. Try again later.

Articles 1–20

Citations per year

Duplicate citations

Merged citations

Add co-authorsCo-authors

Follow

Cited by

Co-authors